Two elderly patients (a 76-year-old man and a 75-year-old woman), who had been previously diagnosed with familial hypercholesterolemia (at 58 and 48 years of age, respectively) underwent long-term treatment with oral therapy and low-density lipoprotein (LDL) apheresis. As their LDL cholesterol levels remained high (>150 mg/dL and >120 mg/dL, respectively) and their familial hypercholesterolemia was complicated with angina pectoris, we added evolocumab to their prescription. Thereafter, their LDL cholesterol levels decreased rapidly, and the patients were successfully weaned from LDL apheresis. Evolocumab therapy should thus be considered when LDL apheresis cannot achieve the target LDL cholesterol levels, though the prognosis of such treatment remains unclear.
Introduction
Hypercholesterolemia is a known risk factor for cardiovascular disease (CVD), and reducing the levels of lowdensity lipoprotein (LDL) cholesterol is important for decreasing the risk for CVD (1, 2) . Hence, several guidelines stated that lowering LDL cholesterol (LDL-C) represents a therapeutic target (3, 4) . Among patients with hypercholesterolemia, those with familial hypercholesterolemia (FH) typically exhibit extremely high levels of LDL-C, the rapid progression of atherosclerotic diseases, and a high prevalence of CVD. Hence, to prevent CVD, the rigorous control of LDL-C is important in patients with FH. When LDL-C is not effectively controlled by oral therapy alone, LDL apheresis (LDL-A) is sometimes used, with relatively good results (5, 6) . While LDL-A is indeed effective in reducing LDL-C, certain procedure-related aspects such as restraint time and vascular access remain matters of concern.
Evolocumab, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, has recently become available. Evolocumab represents a promising drug, as it is reported to reduce the risk of CVD in patients with hypercholesterolemia, including those with FH (7). Furthermore, the efficacy of evolocumab in reducing LDL-C in FH patients has been reported (8, 9) . However, these trials did not include FH patients receiving LDL-A. There are no reports on the effects of evolocumab therapy combined with LDL-A. We herein report 2 cases of FH in which evolocumab treatment enabled the patients to be successful weaned from LDL-A. oral therapy. Thereafter, he experienced angina pectoris 5 times, which was managed via percutaneous coronary intervention (4 times) and coronary artery bypass grafting (once). A further complication of bilateral carotid artery stenosis was treated via bilateral carotid endarterectomy.
In March 2016, when the patient was 76 years of age, he presented to our department with consistently high levels of LDL-C despite the ongoing treatment. At the time, the patient's prescription for oral therapy included rosuvastatin (2.5 mg/day), aspirin (100 mg/day), indapamide (1 mg/day), lansoprazole (15 mg/day), ethyl-eicosapentaenoic acid (1,800 mg/day), carvedilol (20 mg/day), aliskiren (300 mg/ day), ezetimibe (10 mg/day), and benidipine (8 mg/day). For this patient, the dosage of rosuvastatin represented the maximum tolerated dose, as he exhibited muscle pain that was associated with the administration of rosuvastatin. In addition to the oral therapy, the patient underwent LDL-A approximately once a month. LDL-A was performed with a system using dextran sulfate cellulose columns (Liposorber LA-15 , Kaneka Medix, Osaka, Japan). The amount of processed plasma was 4,000 mL/session; heparin was used as an anticoagulant. Because few good vessels for use in vascular access remained, an arteriovenous fistula was created in his left forearm to serve as vascular access (the same as for hemodialysis).
With the above-described treatment strategy, the levels of LDL-C before the LDL-A sessions were maintained at approximately 150 mg/dL. For the secondary prevention of CVD, we aimed to achieve a significant decrease in the levels of LDL-C. Our first suggestion was to increase the frequency of LDL-A, which was refused by the patient on account of the long restraint time during treatment and discomfort related to the urge to urinate. In May 2016, the patient was started on evolocumab (140 mg every 2 weeks). Thereafter, the levels of LDL-C rapidly decreased. Fig. 1 shows the evolution of the LDL-C levels, which remained below 100 mg/dL as soon as evolocumab therapy was initiated. Thereafter, the patient was successfully weaned from LDL-A. Table 1 shows the results of the laboratory investigations that were performed before the final LDL-A session and at 2 weeks after the final LDL-A session.
Case 2
A 75-year-old woman experienced myocardial infarction at 48 years of age, and exhibited high levels of total cholesterol (>500 mg/dL). The patient had a family history of cardiovascular events, as her mother had died from myocardial infarction in her 30s, and her daughter had hypercholesterolemia. The patient showed xanthoma on her Achilles tendon, cubital fossa, and her back. At the time, she was diagnosed with FH according to the Simon Broome criteria. At 55 years of age, the patient was started on LDL-A, in addition to her ongoing oral therapy. Thereafter, the patient experienced angina pectoris once.
In March 2016, when the patient was 75 years of age, she presented to our department with consistently high levels of LDL-C despite the ongoing treatment. At the time, the patient's prescription for oral therapy included rosuvastatin (10 mg/day), aspirin (100 mg/day), lansoprazole (15 mg/day), ethyl-eicosapentaenoic acid (1,800 mg/day), ezetimibe (10 mg/day), bisoprolol (1.25 mg/day), telmisartan (40 mg/day), sodium ferrous citrate (100 mg/day), minodronic acid hydrate (50 mg/month), and paroxetine (25 mg/day). The dose of rosuvastatin represented the maximum tolerated dose, as the patient experienced muscular pain related to the administration of rosuvastatin. In additional to oral therapy, the patient underwent LDL-A once a month. LDL-A was performed as described in case 1.
With the above-described treatment strategy, the levels of LDL-C were maintained at approximately 120 mg/dL. As in the previous case, we first suggested to increase the frequency of LDL-A, but the patient refused on account of the long restraint time during treatment and discomfort related to the urge to urinate. In June 2016, the patient was started on evolocumab (140 mg every 2 weeks). Thereafter, the levels of LDL-C decreased rapidly. Fig. 2 shows the evolution of LDL-C levels, which remained below 100 mg/dL as soon as evolocumab therapy was initiated. Thereafter, the patient was successfully weaned from LDL-A. Table 2 shows the results of the laboratory investigations that were performed before the final LDL-A session and at 2 weeks after the final LDL-A session.
Discussion
We herein describe 2 cases of FH in which LDL-C could not be sufficiently controlled via oral therapy and LDL-A, but in which the LDL-C levels were successfully managed and weaning from LDL-A became possible after the addition of evolocumab. Increasing the frequency of LDL-A might have also helped to reduce their LDL-C levels; however, neither patient agreed to this option due to the long restraint time and discomfort associated with the LDL-A sessions.
Evolocumab has been reported to reduce the risk of CVD (7) and the levels of LDL-C in FH patients (8, 9) . Our report adds to the current evidence of the efficacy of evolocumab in the treatment of FH patients receiving LDL-A, and suggests that it can reduce the levels of LDL-C to a greater extent than is possible with LDL-A combined with oral therapy. The guidelines put forward by the Japan Atherosclerosis Society (4) specify a target LDL-C level of <100 mg/dL for the secondary prevention of CVD. However, such a target is sometimes difficult to achieve in FH patients. Based on the observations in the two cases of the present study, we recommend that physicians consider adding evolocumab when the target LDL-C levels cannot be achieved in FH patients receiving LDL-A.
Evolocumab, which is a type of PCSK9 inhibitor, is believed to decrease the levels of LDL-C by upregulating the recycling of the LDL receptor, which is responsible for removing LDL-C from the bloodstream by means of endocytosis (11, 12) . Given this mechanism of action, the efficacy of PCSK9 inhibitors is expected to be low in patients with homozygous LDL receptor mutations that lead to the complete depletion of the LDL receptor. Based on the response of our patients' LDL-C levels to evolocumab treatment, we assume that they represent cases of heterozygous FH; however, we did not perform any genetic testing to confirm the nature of their mutations. We believe that PCSK9 inhibitors represent a promising treatment when a residual LDL receptor is available.
The optimal choice of treatment (i.e., LDL-A or evolocumab) for improving the prognosis of FH patients remains an important topic for discussion. From the patient's perspective, the major disadvantages of LDL-A are the long restraint time during treatment sessions, as well as the discomfort related to ensuring suitable vascular access. In one of our patients, vascular access for LDL-A was achieved in the same manner as in hemodialysis patients. However, while LDL-A is effective in reducing the levels of LDL-C, the effect is short-lived, and the LDL-C levels reach abnormal values within 1 or 2 weeks (13, 14) . On the other hand, LDL-A has pleiotropic effects, which include the improvement the vascular endothelial function by decreasing the oxidative stress responses and inhibiting nitric oxide synthesis (15) , and the improvement of the rheological properties of the blood (16, 17) . Hence, aside from its ability to lower the LDL-C levels, LDL-A may be more effective in alleviating arteriosclerotic disease. On the other hand, evolocumab may have the advantage of continuously maintaining low LDL-C levels, whereas these levels are expected to recover within 1 to 2 weeks after an LDL-A session (13, 14) . Furthermore, as of 2016, the cost of evolocumab therapy (140 mg, twice per month) in Japan amounts to approximately one-third of the cost associated with LDL-A (once per month), which represents another advantage of evolocumab therapy. With respect to the cases of the present study, although the choice for evolocumab therapy was based on the patients' preference, we cannot state without doubt that such a clinical course should become standard for FH patients, as we did not evaluate the long-term prognosis of our patients. The optimal treatment choice for such patients, in terms of the prognosis, remains unclear. A notable limitation of our investigation is that we did not perform genetic testing. Thus, we could not determine the location of the FH-inducing mutation in our patients, and were unable to assess the effectiveness of evolocumab therapy in the context of the genetic nature of FH.
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